Metraipolis › archive › dc_8129c8cf4841

Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis — Europe PMC PMID:42268869

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42268869
DOI: 10.1371/journal.pone.0351059
License (as archived): solo-consultazione
Archived: 2026-10-07T14:12:42.970Z
SHA-256 of the archived text: 9383f300b6c51f324a275eb20443328254ae1230a0d5346103abd9e53375993b
Stable URL of this page: https://metraipolis.com/documento/dc_8129c8cf4841

How to cite

Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis — Europe PMC PMID:42268869 — Europe PMC (en), https://europepmc.org/article/MED/42268869 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8129c8cf4841 (Metraipolis archive dc_8129c8cf4841, sha256 9383f300b6c51f324a275eb20443328254ae1230a0d5346103abd9e53375993b)

BibTeX

@misc{dc8129c8cf4841,
  title = {Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis — Europe PMC PMID:42268869},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42268869},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8129c8cf4841; sha256 9383f300b6c51f324a275eb20443328254ae1230a0d5346103abd9e53375993b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42268869. Agents can read the archived copy with the MCP tool read_document.